Dr. Reddy's Laboratories DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.78×	0.77×	0.75×	0.78×	0.75×
	1.30×	1.22×	1.12×	1.11×	1.18×
	8.2%	13.0%	21.0%	23.1%	20.7%
	0.63×	0.63×	0.74×	0.79×	0.80×
	1.47×	1.52×	1.46×	1.38×	1.39×
	7.7%	11.8%	18.9%	21.6%	20.3%
	11.8%	11.8%	18.3%	21.6%	21.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DRREDDY₹1,345.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.12L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.78	0.75	0.77	0.78
Interest Burden (Pretax/EBIT) ×	1.18	1.11	1.12	1.22	1.30
EBIT Margin %	20.67	23.07	20.96	13.04	8.22
Asset Turnover ×	0.80	0.79	0.74	0.63	0.63
Financial Leverage (Assets/Equity) ×	1.39	1.38	1.46	1.52	1.47
ROE (5-step product, year-end total equity) %	20.27	21.64	18.91	11.82	7.74
ROE (owners' profit / average owners' equity) %	21.21	21.64	18.30	11.75	11.75

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.